000139181 001__ 139181
000139181 005__ 20240321220554.0
000139181 0247_ $$2doi$$a10.1016/j.nlm.2017.02.006
000139181 0247_ $$2pmid$$apmid:28215510
000139181 0247_ $$2ISSN$$a1074-7427
000139181 0247_ $$2ISSN$$a1095-9564
000139181 037__ $$aDZNE-2020-05503
000139181 041__ $$aEnglish
000139181 082__ $$a570
000139181 1001_ $$0P:(DE-HGF)0$$aColas, Damien$$b0$$eCorresponding author
000139181 245__ $$aShort-term treatment with flumazenil restores long-term object memory in a mouse model of Down syndrome.
000139181 260__ $$aOrlando, Fla.$$bAcademic Press$$c2017
000139181 264_1 $$2Crossref$$3print$$bElsevier BV$$c2017-04-01
000139181 3367_ $$2DRIVER$$aarticle
000139181 3367_ $$2DataCite$$aOutput Types/Journal article
000139181 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1587035958_2267
000139181 3367_ $$2BibTeX$$aARTICLE
000139181 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000139181 3367_ $$00$$2EndNote$$aJournal Article
000139181 520__ $$aDown syndrome (DS) is a common genetic cause of intellectual disability yet no pro-cognitive drug therapies are approved for human use. Mechanistic studies in a mouse model of DS (Ts65Dn mice) demonstrate that impaired cognitive function is due to excessive neuronal inhibitory tone. These deficits are normalized by chronic, short-term low doses of GABAA receptor (GABAAR) antagonists in adult animals, but none of the compounds investigated are approved for human use. We explored the therapeutic potential of flumazenil (FLUM), a GABAAR antagonist working at the benzodiazepine binding site that has FDA approval. Long-term memory was assessed by the Novel Object Recognition (NOR) testing in Ts65Dn mice after acute or short-term chronic treatment with FLUM. Short-term, low, chronic dose regimens of FLUM elicit long-lasting (>1week) normalization of cognitive function in both young and aged mice. FLUM at low dosages produces long lasting cognitive improvements and has the potential of fulfilling an unmet therapeutic need in DS.
000139181 536__ $$0G:(DE-HGF)POF3-341$$a341 - Molecular Signaling (POF3-341)$$cPOF3-341$$fPOF III$$x0
000139181 542__ $$2Crossref$$i2017-04-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000139181 588__ $$aDataset connected to CrossRef, PubMed,
000139181 650_7 $$2NLM Chemicals$$aGABA Modulators
000139181 650_7 $$040P7XK9392$$2NLM Chemicals$$aFlumazenil
000139181 650_2 $$2MeSH$$aAnimals
000139181 650_2 $$2MeSH$$aCognition: drug effects
000139181 650_2 $$2MeSH$$aDisease Models, Animal
000139181 650_2 $$2MeSH$$aDown Syndrome: drug therapy
000139181 650_2 $$2MeSH$$aDown Syndrome: genetics
000139181 650_2 $$2MeSH$$aFlumazenil: pharmacology
000139181 650_2 $$2MeSH$$aFlumazenil: therapeutic use
000139181 650_2 $$2MeSH$$aGABA Modulators: pharmacology
000139181 650_2 $$2MeSH$$aGABA Modulators: therapeutic use
000139181 650_2 $$2MeSH$$aMale
000139181 650_2 $$2MeSH$$aMemory Disorders: drug therapy
000139181 650_2 $$2MeSH$$aMemory, Long-Term: drug effects
000139181 650_2 $$2MeSH$$aMice
000139181 7001_ $$0P:(DE-HGF)0$$aChuluun, Bayarsaikhan$$b1$$eCorresponding author
000139181 7001_ $$0P:(DE-2719)2810922$$aGarner, Craig C$$b2$$eCorresponding author$$udzne
000139181 7001_ $$0P:(DE-HGF)0$$aHeller, H Craig$$b3$$eCorresponding author
000139181 77318 $$2Crossref$$3journal-article$$a10.1016/j.nlm.2017.02.006$$b : Elsevier BV, 2017-04-01$$p11-16$$tNeurobiology of Learning and Memory$$v140$$x1074-7427$$y2017
000139181 773__ $$0PERI:(DE-600)1471414-0$$a10.1016/j.nlm.2017.02.006$$gVol. 140, p. 11 - 16$$p11-16$$q140<11 - 16$$tNeurobiology of learning and memory$$v140$$x1074-7427$$y2017
000139181 909CO $$ooai:pub.dzne.de:139181$$pVDB
000139181 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810922$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000139181 9131_ $$0G:(DE-HGF)POF3-341$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$aDE-HGF$$bForschungsbereich Gesundheit$$lErkrankungen des Nervensystems$$vMolecular Signaling$$x0
000139181 9141_ $$y2017
000139181 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-17$$wger
000139181 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROBIOL LEARN MEM : 2021$$d2022-11-17
000139181 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000139181 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000139181 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-17
000139181 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-17
000139181 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000139181 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000139181 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-17
000139181 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-17
000139181 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2022-11-17
000139181 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-17
000139181 9201_ $$0I:(DE-2719)1810001$$kAG Garner$$lSynaptopathy$$x0
000139181 980__ $$ajournal
000139181 980__ $$aVDB
000139181 980__ $$aI:(DE-2719)1810001
000139181 980__ $$aUNRESTRICTED